Breast cancer tumors grow faster in younger women

May 08, 2008

A new approach to estimating tumour growth based on breast screening results from almost 400,000 women is published today BioMed Central’s open access journal, Breast Cancer Research. This new model can also estimate the proportion of breast cancers which are detected at screening (screen test sensitivity). It provides a new approach to simultaneously estimating the growth rate of breast cancer and the ability of mammography screening to detect tumours.

The results of the study show that tumour growth rates vary considerably among patients, with generally slower growth rates with increasing age at diagnosis. Understanding how tumours grow is important in the planning and evaluation of screening programs, clinical trials, and epidemiological studies.

However, studies of tumour growth rates in people have so far been based mainly on small and selected samples. Now, Harald Weedon-Fekjær of the Department of Etiological Research, Cancer Registry of Norway and colleagues have developed a new estimating procedure to follow tumour growth in a very large population of breast cancer patients included in the Norwegian Breast Cancer Screening Program.

The researchers applied their model to cancer incidence and tumour measurement data from 395,188 women aged between 50 and 69 years old. They found that tumour growth varies considerably between subjects. About one in twenty tumours double in size in just over a month from 10 to 20mm, while similar numbers took more than six years to grow to this size. They estimated the mean time for a tumour to double in size from 10 to 20 mm in diameter is 1.7 years.

“There are enormous implications for the sensitivity of breast cancer screening programs” Weedon-Fekjær explains. “We found that mammography screen test sensitivity (STS) increases sharply with increased tumour size, as one might expect. Detection rates are just 26% for a 5 mm tumour but increase to 91% once a tumour is 10 mm in size.” The team compared their model with the previously used Markov model for tumour progression, and found its predictive power to be almost twice as accurate as the Markov model, in addition to providing new estimates directly linked to tumour size.

Source: BioMed Central

Explore further: Mammography benefits overestimated, review says

Related Stories

Single cells seen in unprecedented detail

Apr 27, 2015

Researchers have developed a large-scale sequencing technique called Genome and Transcriptome Sequencing (G&T-seq) that reveals, simultaneously, the unique genome sequence of a single cell and the activity ...

Twist1: Complex regulator of cell shape and function

Jan 20, 2015

Transcription factor Twist1 is involved in many processes where cells change shape or function. Thereby, Twist1 is crucial for embryonic development, but has also been implicated in cancer progression. However, the precise ...

How scorpion venom could yield new cancer treatment

Jan 07, 2015

In the development of new drugs, taking something from nature and modifying it has been a successful tactic employed by medicinal chemists for years. Now, with the help of nanotechnology, researchers are ...

Recommended for you

Mammography benefits overestimated, review says

5 hours ago

An in-depth review of randomised trials on screening for breast, colorectal, cervical, prostate and lung cancers, published in the Journal of the Royal Society of Medicine, shows that the benefits of mammographic screening are li ...

Extended-field IMRT does not increase duodenal toxicity risk

7 hours ago

A study of women with cervical or endometrial cancer who require treatment to the para-aortic (PA) lymph nodes can safely receive extended-field intensity modulated radiation therapy (EF-IMRT) without increased risk of duodenal ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.